Abstract: The present application can provide an electrode, a method of manufacturing an electrode, and a use of the electrode. The present application can provide an electrode without forming the fat edge portion while an insulating layer formed by overlapping with the electrode active material layer on the current collector layer of the electrode effectively secures the insulation required for the electrode. In addition, even when the electrode design model is changed, the present application can provide a manufacturing method capable of manufacturing the above-described electrode by flexibly responding to the relevant change. In addition, the present application can provide a use of the electrode.

Abstract: The present invention relates to a novel polycyclic compound employed in an organic layer of an organoelectro luminescent device, wherein the organoelectro luminescent device employing the compound according to the present invention has remarkably improved luminous efficiency and a long lifespan. According to the present invention, it is possible to implement a highly efficient and long-life organoelectro luminescent device that can be effectively applied to various display devices.

Abstract: A complementary thin film transistor (TFT) includes a substrate and a first TFT and a second TFT disposed on the substrate, wherein a first conductive semiconductor layer of the first TFT and a second gate electrode layer of the second TFT are disposed in the same layer and include the same material.

Abstract: Disclosed are a cathode for an all-solid-state battery including a cathode thin film for an all-solid-state battery or a cathode composite membrane for an all-solid-state battery, and an all-solid-state battery including the same. The cathode for an all-solid-state battery contains a grain that has a plane having a low surface energy and has a grain boundary arranged parallel to the electron movement direction, thus effectively lowering the interfacial resistance of the thin film while suppressing the dissolution and diffusion of the transition metal, thereby improving the cycle stability of the all-solid-state battery including the same.

Abstract: Disclosed is a method of manufacturing a solid oxide fuel cell including a multi-layered electrolyte layer using a calendering process. The method for manufacturing a solid oxide fuel cell is a continuous process, thus providing high productivity and maximizing facility investment and processing costs. In addition, the solid oxide fuel cell manufactured by the method includes an anode that is free of interfacial defects and has a uniform packing structure, thereby advantageously greatly improving the production yield and power density. In addition, the solid oxide fuel cell has excellent interfacial bonding strength between respective layers included therein, and includes a multi-layered electrolyte layer in which the secondary phase at the interface is suppressed and which has increased density, thereby advantageously providing excellent output characteristics and long-term stability even at an intermediate operating temperature.

Abstract: Disclosed is an anode-free all-solid-state battery having improved charge/discharge cycle stability. Specifically, the anode-free all-solid-state battery includes a cathode layer containing a cathode active material, an anode current collector layer, and a solid electrolyte layer interposed between the cathode layer and the anode current collector layer, wherein the anode current collector layer has a surface roughness (Rq) of 100 nm to 1,000 nm.

Abstract: Provided are a lithium-argyrodite ionic superconductor containing a halogen element and a method for preparing the same, wherein an argyrodite-type crystal structure can be maintained and lithium ion conductivity can be greatly improved by combining specific elements at a specific molar ratio.

Abstract: Disclosed is a method of manufacturing a solid oxide fuel cell including a multi-layered electrolyte layer using a calendering process. The method for manufacturing a solid oxide fuel cell is a continuous process, thus providing high productivity and maximizing facility investment and processing costs. In addition, the solid oxide fuel cell manufactured by the method includes an anode that is free of interfacial defects and has a uniform packing structure, thereby advantageously greatly improving the production yield and power density. In addition, the solid oxide fuel cell has excellent interfacial bonding strength between respective layers included therein, and includes a multi-layered electrolyte layer in which the secondary phase at the interface is suppressed and which has increased density, thereby advantageously providing excellent output characteristics and long-term stability even at an intermediate operating temperature.

Abstract: Disclosed are a cathode for an all-solid-state battery including a cathode thin film for an all-solid-state battery or a cathode composite membrane for an all-solid-state battery, and an all-solid-state battery including the same. The cathode for an all-solid-state battery contains a grain that has a plane having a low surface energy and has a grain boundary arranged parallel to the electron movement direction, thus effectively lowering the interfacial resistance of the thin film while suppressing the dissolution and diffusion of the transition metal, thereby improving the cycle stability of the all-solid-state battery including the same.

Abstract: There is provided a method for the isolation and cultivation of mesenchymal stem/progenitor cells from umbilical cord blood, and also to a method for the differentiation of the umbilical cord blood-derived mesenchymal stem/progenitor cells into various mesenchymal tissues. The method include overlaying umbilical cord blood onto Ficoll-Hypaque solution; centrifuging the umbilical cord blood on the Ficoll-Hypaque solution to obtain a mononuclear cell layer; reacting cells obtained by monolayer culture of the mononuclear cells with antibodies to mesenchymal stem/progenitor cell-specific antigens for a predetermined period of incubation time; isolating only cells bound to their corresponding antibodies using a cell sorter; and cultivating the isolated cells, thereby obtaining mesenchymal stem/progenitor cells with high purity and excellent viability.

Abstract: Disclosed is a composition for the treatment of cartilage or bone damage or loss or defect. The composition comprises mesenchymal stem cells separated from umbilical cord blood and/or mesenchymal stem cells proliferated and/or differentiated. The composition also comprise chondrocytes and/or chondroblasts, or osteocytes and/or osteoblasts, differentiated from the mesenchymal stem cells separated from the umbilical cord blood.

Abstract: Disclosed is a composition for the treatment of cartilage or bone damage or loss or defect. The composition comprises mesenchymal stem cells separated from umbilical cord blood and/or mesenchymal stem cells proliferated and/or differentiated. The composition also comprise chondrocytes and/or chondroblasts, or osteocytes and/or osteoblasts, differentiated from the mesenchymal stem cells separated from the umbilical cord blood.

Abstract: Disclosed is a composition for the treatment of cartilage or bone damage or loss or defect. The composition comprises mesenchymal stem cells separated from umbilical cord blood and/or mesenchymal stem cells proliferated and/or differentiated. The composition also comprise chondrocytes and/or chondroblasts, or osteocytes and/or osteoblasts, differentiated from the mesenchymal stem cells separated from the umbilical cord blood.

Abstract: Disclosed herein is a composition for the treatment of articular cartilage damage or loss or defect. The composition for the treatment of articular cartilage injury of the present invention includes (i) cellular components separated, proliferated, and/or differentiated from the umbilical cord blood, (ii) a culture medium; and (iii) a biocompatible polymer. The composition has very superior ability of proliferation and differentiation and easier to be collected and acquired.

Abstract: The present application discloses a method for expanding a population of mammalian cells comprising contacting the cells with angiopoietin 1.

Abstract: The present invention relates to a method for the isolation and cultivation of mesenchymal stem/progenitor cells from umbilical cord blood, and also to a method for the differentiation of the umbilical cord blood-derived mesenchymal stem/progenitor cells into various mesenchymal tissues. The method comprises the steps of: overlaying umbilical cord blood onto Ficoll-Hypaque solution; centrifuging the umbilical cord blood on the Ficoll-Hypaque solution to obtain a mononuclear cell layer; reacting cells obtained by monolayer culture of the mononuclear cells with antibodies to mesenchymal stem/progenitor cell-specific antigens for a predetermined period of incubation time; isolating only cells bound to their corresponding antibodies using a cell sorter; and cultivating the isolated cells, thereby obtaining mesenchymal stem/progenitor cells with high purity and excellent viability.

Abstract: The present invention is related to a composition for the treatment of articular cartilage damage or loss or defect. The composition for the treatment of articular cartilage injury of the present invention is characterized by that it is composed of cellular components separated, proliferated, and/or differentiated from the umbilical cord blood and their media, or of the above cellular components, their media, and biocompatible polymers. Compared to the conventional cells used for the treatment of articular cartilage damage, cellular components of the composition of the present invention have very superior ability of proliferation and differentiation and more easy to be collected and acquired.